https://www.selleckchem.com/pr....oducts/lixisenatide.
We demonstrated that miR-1299 inhibits the progression of NSCLC through the EGFR/PI3K/Akt signal pathway. Therapeutic intervention targeting the miR-1299 may provide a potential strategy for the treatment of NSCLC. We demonstrated that miR-1299 inhibits the progression of NSCLC through the EGFR/PI3K/Akt signal pathway. Therapeutic intervention targeting the miR-1299 may provide a potential strategy for the treatment of NSCLC. The microRNA (miRNA) profile changes in the tumor-associated macrophages. However, the role of miR-106b-5p
Like
Comment
Share
